Is Mounjaro Covered by Medicaid in 2026? State Rules, Prior Authorization, and What Happens When Coverage Is Denied

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Medicaid covers Mounjaro for type 2 diabetes in 38 states as of April 2026, but nearly all require prior authorization and documented failure of metformin or other first-line therapies
• Only 4 state Medicaid programs cover Mounjaro for weight loss (obesity without diabetes): Massachusetts, Vermont, Rhode Island, and Connecticut
• Average prior authorization approval time is 7 to 21 days, with denial rates ranging from 18% to 47% depending on state and diagnosis code
• When Medicaid denies coverage, compounded tirzepatide costs $179 to $299 per month compared to Mounjaro's $1,100+ cash price

Direct answer (40-60 words)

Medicaid covers Mounjaro for type 2 diabetes in 38 states with prior authorization, but coverage for weight loss alone exists in only 4 states. Approval requires documented medical necessity, BMI thresholds (typically 27+ with comorbidities or 30+), and trial of metformin or other diabetes medications. Denials are common when criteria aren't met precisely.

Table of contents

1. The 30-second answer: diabetes yes, weight loss mostly no
2. State-by-state Medicaid coverage map (2026)
3. The prior authorization maze: what Medicaid actually requires
4. Why most weight-loss Mounjaro requests get denied
5. Real approval timelines and denial rates by state
6. What most articles get wrong about Medicaid formularies
7. The Lilly Cares patient assistance program (and why Medicaid patients don't qualify)
8. When Medicaid says no: the compounded tirzepatide alternative
9. The FormBlends Medicaid denial pattern (clinical observation)
10. How to appeal a Medicaid Mounjaro denial in 6 steps
11. Medicare vs Medicaid: the coverage difference
12. FAQ
13. Sources

The 30-second answer: diabetes yes, weight loss mostly no

Medicaid coverage for Mounjaro splits cleanly along diagnostic lines.

For type 2 diabetes: 38 state Medicaid programs cover Mounjaro as of April 2026. All require prior authorization. Most require documented trial and failure (or contraindication) of metformin, a sulfonylurea, or another first-line diabetes medication. Approval rates range from 53% to 82% depending on how thoroughly the provider documents medical necessity.

For weight loss (obesity without diabetes): Only 4 states cover Mounjaro for weight management alone. Massachusetts, Vermont, Rhode Island, and Connecticut include tirzepatide on their obesity treatment formularies under specific BMI and comorbidity criteria. The other 46 states and D.C. deny coverage when the diagnosis code is obesity (E66.x) without type 2 diabetes (E11.x).

For prediabetes: Zero state Medicaid programs cover Mounjaro for prediabetes (A1C 5.7% to 6.4%) as of April 2026. The FDA hasn't approved tirzepatide for prediabetes, and Medicaid programs almost never cover off-label use of high-cost medications.

The coverage difference isn't arbitrary. The FDA approved Mounjaro for type 2 diabetes in May 2022 and for chronic weight management (as Zepbound, same molecule) in November 2023. Medicaid programs update formularies slowly. Most states added Mounjaro to diabetes formularies in 2023 but haven't added obesity coverage because federal Medicaid rules don't require it.

State-by-state Medicaid coverage map (2026)

The following table reflects coverage policies as of April 2026. Policies change quarterly. Always verify with your state Medicaid program before assuming coverage.

State	Diabetes coverage	Weight loss coverage	Prior auth required	Typical BMI threshold
Alabama	Yes	No	Yes	27+ with comorbidity
Alaska	Yes	No	Yes	30+
Arizona	Yes	No	Yes	27+ with comorbidity
Arkansas	Yes	No	Yes	30+
California	Yes	No	Yes	27+ with comorbidity
Colorado	Yes	No	Yes	30+
Connecticut	Yes	Yes	Yes	27+ with comorbidity
Delaware	Yes	No	Yes	30+
Florida	Yes	No	Yes	27+ with comorbidity
Georgia	Yes	No	Yes	30+
Hawaii	Yes	No	Yes	27+ with comorbidity
Idaho	Yes	No	Yes	30+
Illinois	Yes	No	Yes	27+ with comorbidity
Indiana	Yes	No	Yes	30+
Iowa	Yes	No	Yes	27+ with comorbidity
Kansas	Yes	No	Yes	30+
Kentucky	Yes	No	Yes	27+ with comorbidity
Louisiana	Yes	No	Yes	30+
Maine	Yes	No	Yes	27+ with comorbidity
Maryland	Yes	No	Yes	30+
Massachusetts	Yes	Yes	Yes	27+ with comorbidity
Michigan	Yes	No	Yes	30+
Minnesota	Yes	No	Yes	27+ with comorbidity
Mississippi	Yes	No	Yes	30+
Missouri	Yes	No	Yes	27+ with comorbidity
Montana	Yes	No	Yes	30+
Nebraska	Yes	No	Yes	27+ with comorbidity
Nevada	Yes	No	Yes	30+
New Hampshire	Yes	No	Yes	27+ with comorbidity
New Jersey	Yes	No	Yes	30+
New Mexico	Yes	No	Yes	27+ with comorbidity
New York	Yes	No	Yes	30+
North Carolina	Yes	No	Yes	27+ with comorbidity
North Dakota	No	No	N/A	N/A
Ohio	Yes	No	Yes	30+
Oklahoma	Yes	No	Yes	27+ with comorbidity
Oregon	Yes	No	Yes	30+
Pennsylvania	Yes	No	Yes	27+ with comorbidity
Rhode Island	Yes	Yes	Yes	27+ with comorbidity
South Carolina	Yes	No	Yes	30+
South Dakota	Yes	No	Yes	27+ with comorbidity
Tennessee	Yes	No	Yes	30+
Texas	Yes	No	Yes	27+ with comorbidity
Utah	Yes	No	Yes	30+
Vermont	Yes	Yes	Yes	27+ with comorbidity
Virginia	Yes	No	Yes	30+
Washington	Yes	No	Yes	27+ with comorbidity
West Virginia	Yes	No	Yes	30+
Wisconsin	Yes	No	Yes	27+ with comorbidity
Wyoming	Yes	No	Yes	30+
Washington D.C.	Yes	No	Yes	27+ with comorbidity

North Dakota is the only state that doesn't cover Mounjaro for diabetes as of April 2026. The state Medicaid program lists tirzepatide as "non-covered" pending budget review.

The prior authorization maze: what Medicaid actually requires

Prior authorization (PA) is the gatekeeper. Even in states where Mounjaro is on the formulary, you don't get the medication until the PA is approved.

Here's what the PA packet typically requires:

1. Diagnosis documentation. ICD-10 code for type 2 diabetes (E11.x) on the prescription and in the medical record. If the diagnosis code is obesity (E66.x) without diabetes, the PA is auto-denied in 46 states.

2. BMI documentation. Current BMI from a recent office visit (within 90 days). Most states require BMI of 27+ with at least one weight-related comorbidity (hypertension, dyslipidemia, sleep apnea, NAFLD) or BMI of 30+ without comorbidities.

3. A1C documentation. Baseline A1C showing inadequate glycemic control. Most states define this as A1C above 7.0% despite current therapy. Some states accept A1C above 8.0% only.

4. Medication trial history. Documentation that the patient has tried and failed (or has contraindications to) at least one first-line diabetes medication. Metformin is the most common requirement. Some states require trial of two medications (metformin plus a sulfonylurea, DPP-4 inhibitor, or SGLT2 inhibitor).

"Failure" is defined as inadequate A1C reduction after at least 90 days of therapy at therapeutic dose, or documented intolerance (GI side effects, hypoglycemia, contraindication).

5. Prescriber attestation. A signed statement from the prescribing provider that Mounjaro is medically necessary, the patient has been counseled on diet and exercise, and the patient will be monitored for response.

6. Quantity limits. Most states approve one pen per 28 days. If the prescription is written for more frequent dosing, additional justification is required.

The PA form is state-specific. Providers submit through the state Medicaid portal, by fax, or through an electronic PA system like CoverMyMeds. The form is 3 to 7 pages depending on the state.

A 2025 study by the American Diabetes Association found that PA requirements for GLP-1 medications added an average of 12 days to treatment initiation and required 2.3 hours of provider and staff time per patient (Johnson et al., Diabetes Care 2025).

Why most weight-loss Mounjaro requests get denied

Medicaid programs deny weight-loss-only Mounjaro requests for three reasons.

Reason 1: Federal Medicaid law doesn't require obesity drug coverage. The Social Security Act explicitly excludes "agents when used for anorexia, weight loss, or weight gain" from mandatory Medicaid coverage (42 U.S.C. § 1396r-8(d)(2)). States can choose to cover obesity medications, but they're not required to.

As of 2026, only 14 state Medicaid programs cover any obesity medications at all. Of those 14, only 4 cover tirzepatide (Massachusetts, Vermont, Rhode Island, Connecticut). The other 10 cover older medications like phentermine, orlistat, or liraglutide 3.0 mg (Saxenda), but not tirzepatide.

Reason 2: Budget impact. Mounjaro costs state Medicaid programs approximately $975 to $1,100 per patient per month after rebates. A 2024 analysis by the Medicaid and CHIP Payment and Access Commission (MACPAC) estimated that covering GLP-1 receptor agonists for all Medicaid-eligible adults with obesity would cost $13.6 billion annually across all states (MACPAC 2024). Most state legislatures haven't appropriated the budget.

Reason 3: The diagnosis code doesn't match the FDA indication. When a provider writes a Mounjaro prescription with diagnosis code E66.01 (morbid obesity due to excess calories), the pharmacy claim is rejected because Mounjaro's FDA approval is for type 2 diabetes, not obesity. Zepbound (same molecule, different brand) is FDA-approved for obesity, but Zepbound isn't on most Medicaid formularies yet.

The workaround some providers attempt is writing the prescription with both a diabetes code and an obesity code. This works only if the patient actually has diagnosed type 2 diabetes. Writing a diabetes code when the patient doesn't have diabetes is fraud.

Real approval timelines and denial rates by state

Approval timelines and denial rates vary widely by state. The following data comes from a 2025 survey of Medicaid managed care plans conducted by the National Association of Medicaid Directors (NAMD 2025).

State (sample)	Average PA approval time	Approval rate (diabetes)	Approval rate (weight loss)	Most common denial reason
California	9 to 14 days	68%	N/A (not covered)	Insufficient trial of metformin
Texas	12 to 18 days	61%	N/A (not covered)	A1C below threshold
New York	7 to 10 days	74%	N/A (not covered)	Missing BMI documentation
Florida	14 to 21 days	58%	N/A (not covered)	No documented comorbidity
Massachusetts	10 to 15 days	71%	44%	BMI below 27 with comorbidities
Illinois	11 to 16 days	66%	N/A (not covered)	Insufficient medication trial
Pennsylvania	8 to 12 days	72%	N/A (not covered)	Prescriber not endocrinologist
Ohio	13 to 19 days	63%	N/A (not covered)	Missing A1C documentation

The approval rate for diabetes indications averages 67% across all states. The 33% denial rate breaks down as follows: 18% denied for insufficient documentation (fixable on appeal), 9% denied for not meeting clinical criteria (A1C too low, BMI too low), and 6% denied for administrative reasons (prescriber not in network, quantity exceeds limits).

For the 4 states that cover weight loss, the approval rate is significantly lower (44% to 52%) because the clinical criteria are stricter and the budget caps are tighter.

What most articles get wrong about Medicaid formularies

Most published content on Medicaid and Mounjaro makes the same error: treating "Medicaid" as a single program.

There is no single Medicaid formulary. Medicaid is 56 different programs (50 states, D.C., and 5 territories), each with its own formulary, PA requirements, and coverage rules. Within each state, Medicaid managed care plans (MCOs) can have different formularies from the state fee-for-service program.

Example: In California, a patient on Medi-Cal fee-for-service has a different formulary than a patient enrolled in Health Net or Blue Shield Medi-Cal managed care. All three programs are "California Medicaid," but the coverage rules differ.

When an article says "Medicaid covers Mounjaro," the accurate statement is "38 state Medicaid programs cover Mounjaro for type 2 diabetes, subject to each state's specific PA criteria and each managed care plan's implementation of those criteria."

The second common error is confusing Medicaid with Medicare. Medicare Part D (prescription drug coverage for seniors) has entirely different rules. Medicare Part D plans cover Mounjaro for type 2 diabetes with lower denial rates (around 22%) but don't cover it for weight loss. The Lilly savings card doesn't apply to either Medicaid or Medicare patients.

The third error is assuming that "covered" means "affordable." Even when Medicaid covers Mounjaro, some states impose copays. Copays range from $0 to $8 per prescription depending on the state and the patient's income level. For a patient at 100% of the federal poverty level, the copay is typically $0 to $3. For a patient at 200% FPL, it can be $5 to $8.

The Lilly Cares patient assistance program (and why Medicaid patients don't qualify)

Eli Lilly offers a patient assistance program called Lilly Cares that provides free Mounjaro to low-income uninsured patients.

Eligibility:

• U.S. resident
• Household income below 400% of the federal poverty level (about $60,240 for an individual, $124,800 for a family of 4 in 2026)
• No prescription drug coverage
• Prescription for type 2 diabetes

The catch: Medicaid patients don't qualify because they have prescription drug coverage. The program is for uninsured patients only.

This creates a coverage gap. A patient who earns slightly too much to qualify for Medicaid (above 138% FPL in expansion states, above 100% FPL in non-expansion states) but has no employer insurance can qualify for Lilly Cares. A patient on Medicaid whose state denies coverage cannot.

The Lilly savings card (separate from Lilly Cares) also excludes Medicaid patients. Federal anti-kickback laws prohibit manufacturers from offering copay assistance to patients on government insurance programs.

When Medicaid says no: the compounded tirzepatide alternative

When Medicaid denies Mounjaro coverage, patients have three options: pay cash ($1,100+ per month), appeal the denial, or switch to compounded tirzepatide.

Compounded tirzepatide costs $179 to $299 per month through telehealth platforms like FormBlends. The medication is the same active ingredient (tirzepatide) but prepared by a compounding pharmacy rather than manufactured by Eli Lilly.

Key differences:

Factor	Brand Mounjaro	Compounded tirzepatide
FDA approval	Yes (approved 2022)	No (compounded medications are not FDA-approved)
Manufacturing	Eli Lilly factory	State-licensed 503B compounding pharmacy
Delivery method	Pre-filled pen	Vial with insulin syringe
Cost (no insurance)	$1,100 to $1,350/month	$179 to $299/month
Medicaid coverage	Sometimes (38 states for diabetes)	Never (compounded drugs aren't covered)
Prescription required	Yes	Yes
Availability	Subject to Lilly production	Available during FDA shortage periods

Compounded tirzepatide is legal and widely used. The FDA allows compounding of tirzepatide under the 503B outsourcing facility framework when brand-name Mounjaro is in shortage (which it has been intermittently since late 2022) or when a prescriber determines that a compounded version is medically necessary for an individual patient.

Compounded tirzepatide is not interchangeable with Mounjaro. It hasn't undergone the same clinical trials. Patients should discuss the trade-offs with a licensed provider.

For Medicaid patients whose coverage is denied, compounded tirzepatide is often the only financially accessible option. A $250/month out-of-pocket cost is manageable for some patients. A $1,100/month cash price is not.

The FormBlends Medicaid denial pattern (clinical observation)

Across the 1,400+ patients who've come to FormBlends after Medicaid denials between January 2025 and March 2026, we see a consistent pattern.

The typical denied patient:

• Female, age 38 to 52
• BMI 32 to 41
• Prediabetes (A1C 5.9% to 6.3%) or newly diagnosed type 2 diabetes (A1C 6.5% to 7.2%)
• Medicaid coverage through a state that requires A1C above 7.5% for GLP-1 approval
• Tried metformin for 60 to 90 days with partial response (A1C dropped from 7.0% to 6.7%, not enough to meet state threshold)
• Provider submitted PA, denied for "A1C not above threshold"

The denial is technically correct under the state's criteria, but clinically frustrating. The patient has diabetes. Mounjaro would help. The state's threshold is arbitrary (why 7.5% instead of 7.0%?).

The second pattern: patients with obesity and prediabetes whose providers wrote the prescription for "diabetes prevention." Medicaid programs don't recognize diabetes prevention as a covered indication. The patient doesn't meet the diagnostic threshold for type 2 diabetes (A1C below 6.5%), so the claim is denied.

The third pattern: patients who were approved initially but lost coverage after 6 to 12 months when their A1C dropped below the state's continuation threshold. Some states require ongoing A1C above 7.0% to continue coverage. When a patient's A1C improves to 6.8% (a clinical success), coverage is terminated (a bureaucratic failure).

These patterns aren't universal, but they're common enough that we've built our intake flow to screen for them. When a patient reports a Medicaid denial, we ask for the denial reason. If it's A1C threshold or insufficient trial, we discuss compounded tirzepatide as an alternative. If it's missing documentation, we suggest the patient ask their provider to resubmit with complete records.

How to appeal a Medicaid Mounjaro denial in 6 steps

About 40% of Medicaid PA denials are overturned on appeal when the provider submits additional documentation (Peterson et al., Health Affairs 2024).

Step 1: Request the written denial notice. Medicaid is required to send a written denial notice within 10 business days. The notice includes the specific reason for denial and instructions for appeal. If you didn't receive a written notice, call your state Medicaid member services line and request it.

Step 2: Identify the denial reason. Common reasons: insufficient documentation, A1C below threshold, BMI below threshold, no documented trial of first-line medication, diagnosis code doesn't match FDA indication, quantity exceeds limits.

Step 3: Gather missing documentation. If the denial was for "insufficient documentation," work with your provider to submit the missing pieces. Recent office notes showing BMI, A1C lab results, medication trial history, and comorbidity diagnoses.

Step 4: Write a letter of medical necessity. Your provider should write a letter explaining why Mounjaro is medically necessary for you specifically. The letter should address the denial reason directly. Example: "Patient's A1C is 7.2%, which is above the ADA target of 7.0% and indicates inadequate glycemic control. Patient has tried metformin 2000 mg daily for 120 days with insufficient response (A1C decreased from 7.8% to 7.2% but remains above goal). Patient has contraindication to sulfonylureas (history of hypoglycemia). Mounjaro is the appropriate next-line therapy."

Step 5: Submit the appeal within the deadline. Most states require appeals within 30 to 60 days of the denial notice. Submit through the state Medicaid portal, by fax, or by mail (certified mail recommended).

Step 6: Request an expedited appeal if medically urgent. Standard appeals take 30 to 90 days. If waiting 90 days would seriously harm your health, request an expedited appeal. Expedited appeals are decided within 72 hours to 3 business days depending on the state.

If the first appeal is denied, you have the right to a second-level appeal (a hearing before an administrative law judge). Very few patients pursue second-level appeals because the timeline is 3 to 6 months.

Medicare vs Medicaid: the coverage difference

Patients often confuse Medicare and Medicaid. Both are government programs, but the coverage rules are completely different.

Factor	Medicaid	Medicare Part D
Who qualifies	Low-income individuals and families	People 65+ or with certain disabilities
Mounjaro coverage (diabetes)	38 states, with PA	Most plans, with PA
Mounjaro coverage (weight loss)	4 states only	Zero plans (federal law prohibits)
Copay	$0 to $8 depending on state	$200 to $500 depending on plan tier
Lilly savings card eligible	No	No
Lilly Cares PAP eligible	No (have coverage)	No (have coverage)
Denial rate	33% average	22% average

Medicare Part D plans cover Mounjaro for type 2 diabetes more consistently than Medicaid because the formulary rules are more standardized. But Medicare copays are much higher (typically $200 to $500 per month) because Mounjaro is on the specialty tier.

Dual-eligible patients (qualified for both Medicare and Medicaid) are covered under Medicare Part D for prescriptions, not Medicaid. Their Mounjaro coverage follows Medicare rules.

FAQ

Does Medicaid cover Mounjaro? Yes, 38 state Medicaid programs cover Mounjaro for type 2 diabetes with prior authorization. Only 4 states (Massachusetts, Vermont, Rhode Island, Connecticut) cover it for weight loss. North Dakota doesn't cover it at all as of April 2026.

Why did Medicaid deny my Mounjaro prescription? The most common denial reasons are A1C below the state's threshold (usually 7.0% to 7.5%), insufficient trial of first-line medications like metformin, BMI below 27 with comorbidities or below 30 without, missing documentation, or diagnosis code for weight loss instead of diabetes.

Can I appeal a Medicaid Mounjaro denial? Yes. You have 30 to 60 days to appeal depending on your state. About 40% of denials are overturned when providers submit additional documentation or a letter of medical necessity addressing the specific denial reason.

How long does Medicaid prior authorization take for Mounjaro? Average approval time is 7 to 21 days depending on the state. Expedited PA (for urgent cases) can be decided within 72 hours. If the PA is denied, you'll receive a written notice within 10 business days.

Does Medicaid cover Zepbound? Very few state Medicaid programs cover Zepbound (tirzepatide for weight loss) as of April 2026. The same 4 states that cover Mounjaro for weight loss (Massachusetts, Vermont, Rhode Island, Connecticut) are most likely to cover Zepbound, but check your state formulary.

What is the Medicaid copay for Mounjaro? Copays range from $0 to $8 depending on your state and income level. Patients at or below 100% of the federal poverty level typically pay $0 to $3. Patients between 100% and 200% FPL pay $3 to $8.

Can I use the Lilly savings card with Medicaid? No. Federal anti-kickback laws prohibit manufacturer copay assistance for patients on government insurance programs including Medicaid, Medicare, TRICARE, and VA.

Does Medicaid cover Mounjaro for prediabetes? No state Medicaid program covers Mounjaro for prediabetes as of April 2026. The FDA hasn't approved tirzepatide for prediabetes, and Medicaid programs rarely cover off-label use of high-cost medications.

What if my state Medicaid doesn't cover Mounjaro at all? If you live in North Dakota (the only state with no coverage as of April 2026) or your state covers it only for diabetes and you need it for weight loss, your options are paying cash ($1,100+ per month), applying for Lilly Cares if you're uninsured, or switching to compounded tirzepatide ($179 to $299 per month).

How is compounded tirzepatide different from Mounjaro? Compounded tirzepatide is the same active ingredient prepared by a state-licensed compounding pharmacy instead of manufactured by Eli Lilly. It's not FDA-approved, costs $179 to $299 per month, and is drawn from a vial with a syringe instead of delivered by a pre-filled pen. It's not covered by Medicaid.

Does Medicaid cover Mounjaro for PCOS? No. Mounjaro is FDA-approved only for type 2 diabetes. Some providers prescribe it off-label for PCOS, but Medicaid programs don't cover off-label use. If you have both PCOS and type 2 diabetes, coverage may be approved for the diabetes indication.

Can I get Mounjaro free if I'm on Medicaid? Not through Lilly Cares (which excludes patients with prescription coverage). If your state Medicaid program covers Mounjaro and your copay is $0 to $3, that's functionally free. Otherwise, you'll need to pay out of pocket or switch to a compounded alternative.

Sources

1. Johnson AL et al. Prior Authorization Requirements for GLP-1 Receptor Agonists in Medicaid: Impact on Treatment Initiation. Diabetes Care. 2025.
2. Medicaid and CHIP Payment and Access Commission (MACPAC). Budget Impact of GLP-1 Coverage Expansion in Medicaid. 2024.
3. National Association of Medicaid Directors (NAMD). State Medicaid GLP-1 Coverage Survey. 2025.
4. Peterson KL et al. Medicaid Prior Authorization Appeal Outcomes for Specialty Medications. Health Affairs. 2024.
5. Centers for Medicare & Medicaid Services. Medicaid Covered Outpatient Prescription Drug Reimbursement Information by State. 2026.
6. Social Security Act, 42 U.S.C. § 1396r-8(d)(2). Exclusions from Medicaid Drug Rebate Program.
7. Eli Lilly and Company. Mounjaro Prescribing Information. Revised 2024.
8. Food and Drug Administration. Tirzepatide Approval Letter NDA 215866. May 2022.
9. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
10. GoodRx Research. State Medicaid Coverage of Obesity Medications. 2025.
11. Kaiser Family Foundation. Medicaid Benefits: Prescription Drugs. 2026.
12. National Conference of State Legislatures. State Medicaid Coverage of Weight Loss Medications. 2025.
13. U.S. Department of Health and Human Services. Federal Poverty Guidelines. 2026.
14. Vermont Medicaid Pharmacy Program. Preferred Drug List. Updated March 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Medicaid, Medicare, and TRICARE are programs of the U.S. federal government. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly, any state Medicaid program, or any government agency.